Cargando…

A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser

BACKGROUND: The Sysmex CN‐6500 is a new haemostasis analyser with an integrated immunoassay module that performs chemiluminescence enzyme assay (CLEIA) in addition to coagulation, turbidimetric, chromogenic and platelet aggregation tests. AIMS: To evaluate the analytical performance of the CN‐6500 a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gardiner, Chris, Lane, Philip, Tailor, Hitesh, Machin, Samuel J., Mackie, Ian J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292606/
https://www.ncbi.nlm.nih.gov/pubmed/34252265
http://dx.doi.org/10.1111/ijlh.13656
_version_ 1784749411954327552
author Gardiner, Chris
Lane, Philip
Tailor, Hitesh
Machin, Samuel J.
Mackie, Ian J.
author_facet Gardiner, Chris
Lane, Philip
Tailor, Hitesh
Machin, Samuel J.
Mackie, Ian J.
author_sort Gardiner, Chris
collection PubMed
description BACKGROUND: The Sysmex CN‐6500 is a new haemostasis analyser with an integrated immunoassay module that performs chemiluminescence enzyme assay (CLEIA) in addition to coagulation, turbidimetric, chromogenic and platelet aggregation tests. AIMS: To evaluate the analytical performance of the CN‐6500 against the predicate device (Sysmex HISCL‐800) for soluble thrombomodulin (TM), thrombin‐antithrombin (TAT), tissue plasminogen activator/plasminogen activator inhibitor 1 complex (tPAI‐C) and plasmin α2 plasmin inhibitor complex (PIC) assays. METHODS: Imprecision was assessed by testing two levels of quality control plasmas 10 times on 5 separate days. Comparability was studied in 230 plasmas from normal donors (n = 30), patients with suspected disseminated intravascular coagulation (DIC, n = 100), sepsis (n = 20) or liver disease (n = 20), lipaemic (n = 20), haemolysed (n = 20) and icteric samples (n = 20). Limit of detection, limit of quantitation and linearity were determined by testing serial dilutions of normal plasma. Sample carryover was assessed by testing samples with high and low normal levels of the analytes concerned. RESULTS: The CN‐6500 performed 21 CLEIA tests per hour, while simultaneously performing coagulation tests. Acceptable between‐run imprecision was obtained using commercial controls with normal and high activity for each analyte (%CV <4%), for all four assays. Excellent linearity was observed (slope 0.89‐1.03; r(2) >0.99) across the measurement range. The lower limits of detection and quantitation were as follows: TM <0.3/0.6 TU/ml, TAT >0.1/<0.2 ng/ml, PIC <0.004/<0.008 µg/ml and tPAI‐C < 0.01/<0.1 ng/ml, respectively. All four assays showed excellent correlation between analysers and were unaffected by haemolysis, icterus or lipaemia. No carryover was observed. CONCLUSIONS: Our data demonstrate that the performance of the CLEIA assays on the CN‐6500 is comparable to that of a stand‐alone immunoassay analyser.
format Online
Article
Text
id pubmed-9292606
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92926062022-07-20 A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser Gardiner, Chris Lane, Philip Tailor, Hitesh Machin, Samuel J. Mackie, Ian J. Int J Lab Hematol ORIGINAL ARTICLES BACKGROUND: The Sysmex CN‐6500 is a new haemostasis analyser with an integrated immunoassay module that performs chemiluminescence enzyme assay (CLEIA) in addition to coagulation, turbidimetric, chromogenic and platelet aggregation tests. AIMS: To evaluate the analytical performance of the CN‐6500 against the predicate device (Sysmex HISCL‐800) for soluble thrombomodulin (TM), thrombin‐antithrombin (TAT), tissue plasminogen activator/plasminogen activator inhibitor 1 complex (tPAI‐C) and plasmin α2 plasmin inhibitor complex (PIC) assays. METHODS: Imprecision was assessed by testing two levels of quality control plasmas 10 times on 5 separate days. Comparability was studied in 230 plasmas from normal donors (n = 30), patients with suspected disseminated intravascular coagulation (DIC, n = 100), sepsis (n = 20) or liver disease (n = 20), lipaemic (n = 20), haemolysed (n = 20) and icteric samples (n = 20). Limit of detection, limit of quantitation and linearity were determined by testing serial dilutions of normal plasma. Sample carryover was assessed by testing samples with high and low normal levels of the analytes concerned. RESULTS: The CN‐6500 performed 21 CLEIA tests per hour, while simultaneously performing coagulation tests. Acceptable between‐run imprecision was obtained using commercial controls with normal and high activity for each analyte (%CV <4%), for all four assays. Excellent linearity was observed (slope 0.89‐1.03; r(2) >0.99) across the measurement range. The lower limits of detection and quantitation were as follows: TM <0.3/0.6 TU/ml, TAT >0.1/<0.2 ng/ml, PIC <0.004/<0.008 µg/ml and tPAI‐C < 0.01/<0.1 ng/ml, respectively. All four assays showed excellent correlation between analysers and were unaffected by haemolysis, icterus or lipaemia. No carryover was observed. CONCLUSIONS: Our data demonstrate that the performance of the CLEIA assays on the CN‐6500 is comparable to that of a stand‐alone immunoassay analyser. John Wiley and Sons Inc. 2021-07-12 2021-12 /pmc/articles/PMC9292606/ /pubmed/34252265 http://dx.doi.org/10.1111/ijlh.13656 Text en © 2021 The Authors. International Journal of Laboratory Hematology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle ORIGINAL ARTICLES
Gardiner, Chris
Lane, Philip
Tailor, Hitesh
Machin, Samuel J.
Mackie, Ian J.
A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser
title A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser
title_full A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser
title_fullStr A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser
title_full_unstemmed A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser
title_short A performance evaluation of chemiluminescence enzyme immunoassays on the Sysmex CN‐6500 haemostasis analyser
title_sort performance evaluation of chemiluminescence enzyme immunoassays on the sysmex cn‐6500 haemostasis analyser
topic ORIGINAL ARTICLES
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292606/
https://www.ncbi.nlm.nih.gov/pubmed/34252265
http://dx.doi.org/10.1111/ijlh.13656
work_keys_str_mv AT gardinerchris aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT lanephilip aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT tailorhitesh aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT machinsamuelj aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT mackieianj aperformanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT gardinerchris performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT lanephilip performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT tailorhitesh performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT machinsamuelj performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser
AT mackieianj performanceevaluationofchemiluminescenceenzymeimmunoassaysonthesysmexcn6500haemostasisanalyser